In brief, we found for the first time that shRNA-mediated repression of DNAJC19 greatly attenuated tumor cell growth and metastasis by regulating PI3K/AKT signaling, providing a novel therapeutic target for NSCLC patients. Here, PIK3CA is linked to non-small cell lung carcinoma.